Illinois Cannabis Industry Sees Financial Boost from Federal Marijuana Policy Shift
A significant change in federal marijuana policy has brought relief to Illinois’ cannabis industry, with companies expected to save tens of millions of dollars in taxes. The Trump administration’s decision to reclassify marijuana from a Schedule I drug to Schedule III has opened the door for expanded medical research and reduced the tax burden on cannabis businesses.
The reclassification move, which takes marijuana out of the same category as heroin and LSD and into a less restrictive classification alongside drugs like ketamine and steroids, has already started to make a difference for companies operating in Illinois. Verano, a Chicago-based cannabis company, says the change allows them to avoid a federal tax rule known as 280E, which previously prevented cannabis companies from writing off normal business expenses.
“This is a momentous shift in our business,” said George Archos, CEO of Verano. “We’ll now be treated no differently than a normal business on the medical component of our sales. So it really helps us grow our company, grow our patient count, our employee count. It’s fantastic for us.”
The reduced tax burden could lead to new facilities, more hiring, and expansion into states that do not yet have medical marijuana programs. Industry leaders hope Illinois can become a model for neighboring states without medical cannabis programs, leading the way for further policy changes.
The reclassification is not the final step, as the federal government is expected to go through additional review, including a formal administrative hearing process, before any broader changes are finalized. However, industry leaders are optimistic that this is just the beginning, and that Illinois can play a key role in shaping the future of marijuana policy in the Midwest.
